Core Viewpoint - The company reported a revenue of RMB 229.1 million for the six months ending June 30, 2025, representing a year-on-year increase of 2.7%, driven by the global commercialization of VitaFlow Liberty® and Alwide®Plus, which significantly boosted overseas revenue by 235.3% compared to the same period in 2024 [1] Financial Performance - The company recorded a net loss of RMB 2.2 million, a significant reduction from the net loss of RMB 57.8 million for the six months ending June 30, 2024 [1] - The improvement in net loss was attributed to stable growth in revenue and gross profit, enhanced operational efficiency through resource optimization and cost control measures, and income generated from the equity sale of its associate company 4C Medical after completing a Series D financing round [1]

Core Viewpoint - The company reported a revenue of 229 million, reflecting a year-on-year increase of 2.67%, while the loss attributable to equity shareholders decreased by 96.17% to 2.163 million [1] Revenue Performance - The increase in revenue is primarily attributed to the ongoing global commercialization of the VitaFlow Liberty® transcatheter aortic valve and its retrievable delivery system, which significantly boosted overseas revenue [1] - The steady progress in the commercialization of the AnchorMan® left atrial appendage occlusion system and the AnchorMan® left atrial appendage guiding system in both China and overseas markets also contributed to revenue growth [1]